J. Greenberg

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

M. Sadelain, K. van Besien, C. Minniti, 2018, Haematologica.

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma

K. van Besien, R. Pearse, P. Christos, 2019, Bone Marrow Transplantation.

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

S. Ely, K. van Besien, R. Pearse, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

K. van Besien, R. Pearse, W. Reid, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

M. Kaminski, J. Leonard, K. Griffith, 2015, Leukemia & lymphoma.

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.

Sonali M. Smith, W. Stock, M. Bishop, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

M. Sadelain, K. van Besien, C. Minniti, 2018, Haematologica.

C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy

J. Atkinson, A. Chadburn, J. Laurence, 2022, Bone Marrow Transplantation.

Towards guidelines for informed consent for prospective stem cell research

J. Greenberg, S. Kidson, D. Smith, 2015 .

Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant

Y. Halvorsen, M. Schuster, R. Gerwien, 2008, Supportive Care in Cancer.

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

J. Leonard, S. Ely, S. Goldsmith, 2015, Leukemia & lymphoma.

Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

J. Leonard, K. van Besien, R. Pearse, 2021, Leukemia & lymphoma.